Published in the African Journal of Laboratory Medicine, the article entitled “The road map for ISO 15189-laboratory accreditation: The Experience of Manhiça Health Research Centre (CISM) laboratory, in southern Mozambique” describes the path followed by the CISM Laboratory between 2012 and 2020 to achieve this important institutional milestone.

With the aim of promoting scientific knowledge sharing and strengthening awareness of this emerging disease, the Manhiça Health Research Centre (CISM) recently hosted the webinar “What Do We Know About Hantavirus?”, a virtual session that brought together healthcare professionals, researchers, students, and representatives of community-based organisations.

Senior researcher at the Manhiça Health Research Centre (CISM), Dr. Inácio Mandomando, from the Bacterial, Viral and Other Neglected Tropical Diseases Research Area, recently completed an approximately seven-week scientific residency at the Institute of Hygiene and Tropical Medicine of NOVA University Lisbon (IHMT NOVA), Portugal, under the FCT Mobility programme.

vete is a young scientist who faces the challenges of being a woman in science on a daily basis. Her story is not only shaped by laboratories and academia, but also by the influences and inspirations that have guided her journey.

CISM has been strengthening regional scientific cooperation to monitor parasite resistance to antimalarial drugs, a phenomenon of concern to public health experts due to its spread and the rapid pace at which it has been advancing in different parts of the world.

A study recently published in the scientific journal BMC Pregnancy and Childbirth, under the PRECISE project (PREgnancy Care Integrating translational Science, Everywhere), reinforces the need to include pregnant women in the continuous surveillance of disease impacts during public health emergencies, such as the COVID-19 pandemic.

The warning comes from a recent scientific review that brings together evidence on the diagnosis, treatment, and clinical management of neonatal malaria and malaria in young infants. The study is particularly relevant for Mozambique, where malaria remains one of the leading causes of illness and child mortality, especially affecting children under five years of age and pregnant women.

he multicenter clinical trial SII-qHPV/MC-03, which evaluates the CERVAVAC vaccine (marketed by Serum Institute of India Pvt. Ltd.), is being conducted in South Africa, Kenya, and Mozambique. In Mozambique, the study is being implemented by the Centro de Investigação em Saúde de Manhiça (CISM), under the leadership of Principal Investigator Tacilta Nhampossa.